CoChat

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

Open access
Takegawa, Naoki, Tsurutani, Junji, Kawakami, Hisato, Yonesaka, Kimio, Kato, Ryoji, Haratani, Koji, Hayashi, Hidetoshi, Takeda, Masayuki, Nonagase, Yoshikane, Maenishi, Osamu, Nakagawa, Kazuhiko · 2019 · International Journal of Cancer
Cited by 90

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an unmet clinical need for the treatment of tumors that express HER2 protein in the absence of HER2 amplification. [fam‐] trastuzumab deruxtecan (DS‐8201a) is a novel antibody–drug conjugate composed of the anti‐HER2 antibody and the topoisomerase I inhibitor, an exatecan derivative. It has shown efficacy against tumors that express HER2 and is currently under evaluation in clinical trials. We here show that the antitumor activity of [fam‐] trastuzumab deruxtecan is dependent on the expression level of HER2 protein in colorectal cancer (CRC) cell lines negative for HER2 amplification. We established isogenic CRC cell lines that express various levels of HER2 protein in the absence of HER2 amplification, and we found that cells that express HER2 at a high level were sensitive to [fam‐] trastuzumab deruxtecan but not to conventional HER2‐targeted therapies. Furthermore, [fam‐] trastuzumab deruxtecan manifested a bystander killing effect both in vitro and in vivo, with cells essentially negative for HER2 expression also being killed in the presence of HER2‐expressing cells, an effect that has the potential to overcome heterogeneity of HER2 expression in CRC tumors. Our results thus suggest that [fam‐] trastuzumab deruxtecan warrants further study as a potential treatment for CRC tumors that express HER2 protein in the absence of HER2 amplification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.32408

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 90

Metadata

Authors
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., & Nakagawa, K.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2019-05-24
Volume
145
Issue
12
Pages
3414-3424
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2946663880
Cited by
90
References
9
FWCI
3.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. https://app.cochat.ai/papers/10.1002/ijc.32408
The paper
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., & Nakagawa, K. (2019). [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. International Journal of Cancer. https://doi.org/10.1002/ijc.32408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.